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ABSTRACT 
 Obesity is one of modern day’s most serious public health concerns, costing 
billions of dollars and claiming millions of lives every year. In addition to being a co-
morbidity for significant health concerns and diseases, obesity has been proven to have 
significant negative effects on the effectiveness of vaccination for the influenza virus. 
The influenza virus is responsible for killing more than 5% of those who contract it. This 
study looks at IL-6 and CRP, inflammation cytokines, to look at the whether increased 
serum levels of IL-6 and CRP in subjects with higher BMI values result in reduced 
responses to vaccination. Results showed that there was no significant correlation 
between IL-6 levels and CRP levels and response to vaccination. Obese subjects did have 
higher levels of these cytokines than literature values for healthy weight individuals. 
Older individuals and high responders to the vaccination were both linked to lower levels 
of IL-6 within the serum. Although no significant results were found, this study should be 
performed again with a larger and more diverse sample size that includes healthy weight 
subjects to better understand the links between serum cytokine levels and response to 
vaccination.  
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CHAPTER 1: INTRODUCTION 
1.1 Obesity 
Obesity has quickly become one of America’s most predominant public health 
concerns. More than one third, or a total of 78.6 million U.S. adults are obese while 2 out 
of three adults are considered to be overweight or obese. Since the early 1960s, the 
prevalence of obesity among adults more than doubled, increasing from 13.4 to 35.7 
percent in U.S. adults age 20 and older.1 Obesity is a multifaceted disorder associated 
with an excessive amount of fat dispersed throughout the body. Excess body fat increases 
the likelihood of health problems and diseases such heart disease, stroke, high blood 
pressure, certain types of cancer, and type 2 diabetes. Furthermore, the obesity epidemic 
costs the United States more than $148 billion a year, with medical costs for obese 
individuals being $1,429 higher than those of healthy weights. In addition to being a 
cosmetic and physical concern, obesity may also result in social and psychological 
concerns.  
Excess weight gain leading up to overweightness and then obesity can be 
attributed to a multitude of genetic, environmental, and lifestyle factors. The most 
common causes of obesity are overeating and physical inactivity where positive energy 
imbalance exists. Genetic factors can influence obesity and can enhance the effects of an 
environment and lifestyle that promotes weight gain. Environmental and social factors 
such as having limited access to nutritious food and adequate resources for physical 
activity can further result in obesity. Additional factors that contribute to obesity include 
the use of certain medications, medical syndromes that limit activity, lack of sleep, and 
pregnancy.  
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Obesity can be determined through skinfold tests, waist circumference measures, 
bioelectric impedance, underwater weighing, or most commonly through the calculation 
of an individual’s body mass index (BMI).3 An individual’s BMI is calculated by 
dividing one’s weight in kilograms by their height squared in meters. According to the 
Centers for Disease Control and Prevention (CDC), an adult with a BMI lower than 18.5 
is classified as underweight, an adult with a BMI between 18.5 and 24.9 is classified as 
healthy weight, an adult with a BMI between 25.0 and 29.9 is classified as overweight, 
and an adult with a BMI 30.0 and above is classified as obese. The most obvious 
limitation to this practice is that BMI makes no distinction between the weight of adipose 
fat and the weight of muscle. Individuals with developed muscles commonly have much 
higher BMIs and may be incorrectly diagnosed as overweight or obese.  
1.2 Influenza Virus  
Influenza is one of the most commonly spread infectious viruses, affecting 
between 5 and 20% of affected Americans every year.8 Influenza is a serious illness that 
can lead to hospitalization or even death. Symptoms of influenza include fever, runny 
nose, coughing, sore throat, muscle aches, fatigue, and headaches. Flu virus transmission 
or “flu season” most commonly occurs in the fall and winter seasons. Populations 
especially susceptible to influenza include the elderly, children, pregnant women, and 
those with weakened immune systems. Modes of transmission include sneezing, 
coughing, or through talking that forms droplets.9 There are three different types of 
influenza virus: influenza A, influenza B, and influenza C. Influenza type A most 
commonly causes pandemics and is most threatening to humans, birds, and pigs. 
Influenza type B infects humans, seals, and ferrets, and influenza type C infects both 
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humans and some animals. Influenza A is composed of 8 RNA segments and is classified 
into subtypes that depend on which hemmagglutinin (HA) protein and neuraminidase 
(NA) protein rests on the viral surface. Furthermore, there are 18 hemagglutinin subtypes 
and 11 neuraminidase subtypes.10 These hemmagglutinin and neuraminidase subtypes 
make up the name of each flu virus. The letters and numbers stand for specific 
components of the virus that set it apart from others.14 In the case of H3N2, the virus has 
hemagglutinin type 3 (H3) and neuraminidase type 2 (N2), constituents that occur on the 
surface of the virus.  
The influenza virus is especially potent because it changes so rapidly through 
antigenic drift and antigenic shift.11 Antigenic drift is a mechanism for variation by 
viruses that involves the accumulation of mutations in the HA and NA viral genes that 
alter the antibody-binding sites so that the mutated viruses escape from antibodies 
generated from the unmutated virus. Although the changes may be miniscule, the new 
virus may not be recognizable by immune cells, making rapid transmission much more 
likely. Antigenic drift occurs in both influenza type A and influenza type B viruses. 
Antigeneic shift is a much more exceptional phenomenon and occurs when a new viral 
strain forms from two different HA and NA proteins to produce a new strain.11  
1.3 Influenza Vaccine 
The influenza vaccine attempts to prevent viral infection and spread of the illness 
by providing active acquired immunity. A vaccine contains agents that resemble disease-
causing microorganisms made from weakened forms of the microbe or surface protein.12 
Exposure to this agent stimulates the body’s immune system to recognize the threat, 
demolish it, and build antibodies to recognize it for a later encounter. This allows the 
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immune system to quickly respond and destroy the virus or agent when it comes into 
contact.  
Everyone 6 months of age or older should get the yearly flu vaccine as early in the 
flu season as possible. The flu vaccination is usually offered by September but is 
continually available through the end of the flu season.8 Since it takes almost two weeks 
after vaccination for antibodies to develop in the body that protect against the influenza 
virus infection, it is recommended that people get vaccinated as early as possible so that 
they are protected before influenza begins spreading in their community.11 A flu vaccine 
is needed on an annual basis because the body’s immune response from vaccination 
declines over time and because flu virus changes every year, meaning a previous year’s 
vaccine will not suffice. Flu vaccines are manufactured in advance based on predictions 
of the upcoming season’s strain. For the 2010-2011 year, the seasonal trivalent flu virus 
was composed of two subtypes of type A influenza and one subtype of type B influenza.12 
There is still a possibility of getting the flu even after getting vaccinated. Factors that 
affect the ability of the flu vaccine to protect a person include the health status and age of 
the person being vaccinated. Additionally, the vaccine can only be effective if the viruses 
used to make the vaccine match those circulating.8  
After vaccination, the immune system responds to the antigens in the vaccine to 
destroy the virus. This stimulates memory B and T cells to recognize the antigen and 
quickly respond to the influenza strain upon later contact. Antigen-specific B 
lymphocytes that were induced during the original exposure remain in the body so that 
cells can quickly remove the infection once it returns.9  
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1.4 Obesity and Influenza Vaccination 
Obesity has been determined to be associated with impaired immune response to 
influenza vaccination.13 An ongoing prospective observational study at the University of 
North Carolina studied any potential links between a higher BMI and immune response 
to the influenza vaccine in human samples. Data from the first two years of the study 
revealed that obese and healthy weight individuals increased their IgG antibodies specific 
for the vaccine one month after vaccination. Conversely, the obese population had a 
greater decline in antibody titers than the healthy weight population one-year post-
vaccination13. This decline in antibody titers in the obese population demonstrates that 
the obesity may have a diminished the immune response to the influenza vaccine. 
Obese individuals showed decreased CD8+ T cell activation and a lower amount of 
functional proteins in comparison to healthy weight individuals. Additionally, diet-
induced obese mice have greater mortality rates to influenza infection and decreased 
innate immune response in comparison to healthy weight mice.13    
1.5 C-Reactive Protein 
C-Reactive Protein (CRP) is a critical component of the immune system produced 
by the liver and released into the blood after infection, tissue injury, or another source of 
inflammation. CRP is a complex set of proteins that was discovered in 1930 as a native 
protein and member of the small pentraxins family5. CRP functions by binding to the 
phosphocholine expressed on the surface of dead cells and then activating a complement 
system that promotes phagocytosis by macrophages. Acute-phase proteins, such as CRP, 
are proteins that increase or decrease in response to inflammation.  This acute-phase 
response occurs as a result of increased interleukin- 6 (IL-6), which is produced by 
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macrophages and adipocytes. Infections, tissue injury, and inflammatory diseases cause 
the release of IL-6 among other cytokines that simulate the production of CRP by the 
liver. Serum CRP levels rise within two hours of inflammation by up to a 50,000-fold 
amount.4 With a consistent half-life of 48 hours, CRP levels are influenced by the rate of 
production and therefore often used a screening for inflammation.  
Genetic and lifestyle factors affect the amount of CRP an individual creates. 
Those who smoke, fail to exercise adequately, or have high blood pressure tend to have 
high levels of CRP.4 Lean and athletic individuals of healthy weight tend to have lower 
levels of CRP in comparison. Genetic factors play an overbearing role in the variation of 
CRP levels as serum levels are inherited from parents and grandparents to children. 
Increased levels of CRP result in increased levels of inflammation, a vital process for 
warding off bacteria, wound healing, and for many critical processes for survival. Recent 
research has revealed that too much inflammation in some circumstances can have 
adverse effects, predominantly on the blood vessels that carry oxygen and nutrients 
throughout the body.5 Atherosclerosis (the process that leads to cholesterol accumulation 
in the arteries) is essentially an inflammatory disorder of the blood vessels, just as 
arthritis is an inflammatory disorder of the bones and joints. Studies have also revealed 
blood markers that reflect the inflammatory process are elevated among individuals at 
high risk for future heart disease. Until recently, available markers of inflammation were 
not suitable for use in physicians’ offices but CRP is very stable and easy to measure. 
1.6 Interleukin 6 
Interleukin 6 (IL-6) is a protein encoded by the IL-6 gene that acts as both a pro-
inflammatory cytokine and as an anti-inflammatory myokine. Macrophages and T cells 
 11"
stimulate immune response to trauma, infection, or other tissue damage that leads to 
inflammation and the secretion of IL-6. IL-6 is capable of crossing the blood-brain barrier 
and beginning synthesis of prostaglandin E2 in the hypothalamus to increase the body’s 
temperature. IL-6 may also be secreted by macrophages in response to pathogen 
associated molecular patterns. These patterns bind to pattern recognition receptors in the 
innate immune system to induce intracellular signaling cascades that result in 
inflammatory cytokine production.  
As a myokine, or a cytokine produced from muscle, IL-6 levels are elevated in 
response to muscle contraction. Therefore, it is significantly elevated with exercise and 
appears before other cytokines in the circulation. IL-6 signals through a type 1 cytokine 
receptor complex composed of the IL-6R alpha chain and the signal-transducing gp130 
component.  
The secretion of IL-6 is regulated by several physiologic and pathologic factors: 
hormones, cytokines, diet, physical activity, stress, hypoxia, and others. IL-6 plays a role 
in stimulating autoimmune and inflammatory processes in diseases such as depression, 
atherosclerosis, arthritis, diabetes, and some cancers. It is produced by many body cells 
such as adipose and liver cells but it is important to note that adipose tissue accounts for 
around 30% of IL-6 production. IL-6 release is related to adipose cells size and 
resultantly increased in obesity. Elevated levels of IL-6 also induce insulin resistance in 
liver and adipose cells by reducing the expression of insulin resistance substrate-1 (IRS-
1)6.  IRS-1 transmits the signal from insulin and insulin-like growth factor receptors to 
the PI3K/Akt and Erk Map kinase pathways to ultimately store glucose. Additionally, 
glucose transporting molecules that are regulated by insulin (GLUT-4) are also reduced 
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in adipose cells, further extending both the signaling and effector sections of insulin 
resistance.  
Combined with the information that obesity has been shown to increase IL-6 and 
CRP serum levels and influenza vaccination is poorer in obese individuals, we wanted to 
investigate if whether these levels were related to BMI, age, and vaccine response in 
obese African-American females. African-American subjects were used in this study 
because they are an understudied population. Lack of adequate representation of African 
Americans in clinical cohorts continues to be the limiting factor in data ascertainment.   
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CHAPTER 2: SPECIFIC AIM AND HYPOTHESIS 
Specific Aim: To measure the levels of IL-6 and CRP in obese African-American 
females and look for correlations between said levels and BMI, age, and vaccine 
response. 
Hypothesis: There will be increased serum levels of IL-6 and CRP in subjects with higher 
BMI values, resulting in reduced vaccination response 
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CHAPTER 3: METHODS 
3.1 Study Design 
The subjects in this study were chosen from participants in an ongoing and 
prospective observational study at the University of North Carolina Family Medicine 
Center in Chapel Hill, NC. The parent study enrolled participants at least 18 years of age 
who were scheduled to receive the 2010-2011 inactive, trivalent seasonal flu vaccine. 
Participants were excluded if they had the following criteria: pregnant or breastfeeding 
women, self-reported use of immunomodulator or immunosuppressive drugs in the last 4 
weeks, acute febrile illness, diseases such as HIV, hepatitis C, and cancer, and a history 
of hypersensitivity to any influenza vaccine components,  
Informed consent, height, weight and baseline blood samples were collected from 
each participant at enrollment. They were then injected with one dose of the 2010-2011 
trivalent inactive (0.5 mL Fluzone (Sanofi Pasteur, Swiftwater, PA, USA) 
A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008 
(Victoria lineage)-like antigens) directly into their deltoid muscle. Participants returned to 
the UNC Family Medical Center 25-35 days after administration of the vaccine to collect 
a post-vaccination blood sample. Serum and peripheral blood mononuclear cells were 
isolated in both blood samples after collection. For this study, 19 total serum samples 
were used from African American women that did not smoke and that did not have 
diabetes. Ages ranged from 20 to 77 years old and BMIs fell between 30 and 61.4. 
Hemagglutination inhibition (HAI) titers were also used in this study, with samples being 
identified as having low (240≤) or high (240≥) HAI Perth (H3N2) antigen values.  
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3.2 Serum Collection 
Serum was collected before receiving the vaccine and then again 25-30 days after 
receiving the vaccine. Pre- and post-vaccine blood draws were collected at the UNC 
Family Medicine Center in Chapel Hill, NC. Blood samples were collected into a 
vacutainer tube and then allowed to clot at room temperature for 30-60 minutes before 
being refrigerated at 4°C. The blood samples were then centrifuged at 800 x g for 10 
minutes at 4°C using the IEC Centra MP4R. Following the centrifugation, 0.5 mL of the 
serum was aliquoted into 1.2 mL serum tubes and then stored in a freezer at a 
temperature of -80°C. 
3.3 Hemagglutination Inhibition Assay 
The hemagglutination inhibition assay is used to measure flu-specific antibody 
levels in blood serum. Serum antibodies to the hemmagglutinin surface glycoprotein 
(HA) interfere with the virus’s ability to attach to red blood cells in this assay. 
Hemagglutination of the red blood cells is inhibited when antibodies are present at a 
sufficient concentration to bind the virus and prevent attachment to the red blood cells. 
Serial dilutions of serum are added to a known concentration of virus and red blood cells. 
The HAI titer is the highest dilution of serum that prevents hemagglutination. If the 
serum contains no antibodies that recognize the influenza strain HA, then red blood cell 
hemagglutination will be observed in all serum dilutions.  
The HAI process began by treating the serum to be tested with receptor-
destroying enzyme (RDE). RDE is used in the HAI test for the influenza virus in order to 
eliminate non-specific hemagglutination inhibitors existing in a serum specimen. RDE 
was added to each sample in a 1:3 ratio and then incubated at 37°C overnight. The 
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samples were cooled after being heat inactivated at 56°C for 1 hour and then 6 parts of 
physiological saline were added. The samples were frozen for 4 hours before use. The 
influenza stock virus was diluted to 8 HAU/50 ul and turkey RBCs were diluted to a 
concentration of 1% solution. Serial dilutions of test serum were added in duplicate to the 
wells of 96-well round bottom plates. Virus and RBCs were added to each well. Positive 
controls, negative controlT, and back titrations of the virus (to confirm virus 
concentration prior to performing the HAI) were also added to each plate.  
Hemagglutination was then read after 30 minutes at room temperature. If serum antibody 
is present, hemagglutination of the RBC will be inhibited.  The HAI titer is the reciprocal 
of the last dilution of serum that completely inhibits hemagglutination.  
3.4 Enzyme-Linked Immunosorbent Assay (ELISA) for Interleukin 6 (IL-6) and C-
reactive protein (CRP) 
The enzyme-linked immunosorbent assay (ELISA) was used to identify the levels 
of influenza-specific cytokines and proteins within the serum. The pro-inflammatory 
cytokine IL-6 and pentameric protein CRP levels were identified in the participants of 
this study. This technique enabled analysis of IL-6 and CRP levels by immobilizing them 
in microplate wells using antigen-antibody binding. The methods employed by these 
ELISAs were quantitative sandwich, or indirect, enzyme immunoassay techniques. A 
monoclonal antibody specific for CRP or IL-6 was pre-coated onto a microplate by the 
manufacturer. Standards and samples were pipetted into the wells and the immobilized 
antibody bound any CRP or IL-6 present. After washing away any unbound substances, 
an enzyme-linked monoclonal antibody specific for CRP or IL-6 was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution 
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was added to the wells and color developed in proportion to the amount of CRP or IL-6 
bound in the primary step. The color development was then stopped and the intensity of 
the color was measured by measuring the optical density using a microplate reader to 
determine the amounts of CRP and IL-6. A standard curve was created for each 
experiment and then the results were compared to each respective standard curve. The 
standard curve was created by plotting the mean absorbance for each standard on the y-
axis against the concentration on the x-axis, and then drawing curve of best fit through 
the points on the graph. This color change signal was measured with an ELISA plate 
reader by measuring the absorbance at 450 nm. Increased enzyme activity (detected by a 
darker color reaction and higher optical density reading) was directly correlated with 
CRP or IL-6 concentration. 
The ELISA procedures took one full day and were run concurrently. For the CRP 
assay, 100 μL of Assay Diluent and 50 μL of the standard or sample were added before 
being incubated for 2 hours. Each well was then aspirated and washed four times before 
adding 200 μL of CRP conjugate to each well and incubating for 2 hours at room 
temperature. The wash process was then repeated and 200 μL of substrate solution was 
added before incubated for 30 minutes at room temperature. 50 μL of stop solution were 
added and then the optical density of each well was recorded using a microplate reader. 
For the IL-6 assay, all the steps were similar except 100 μL of the standard or sample 
were added before the initial incubation. Additionally, the last incubation step after 
adding the substrate solution was 20 minutes rather than 30 minutes.  
Specific Details for Analysis CRP and IL-6 levels in Serum using ELISA: 
Materials 
Clear 96 well plates 
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Plate covers/sealers  
Multi-channel precision pipettors with disposable plastic tips 
Plate Reader 
Reagents 
CRP Conjugate 21 mL of monoclonal antibody against CRP conjugated to 
horseradish peroxidase with preservatives 
CRP Standard 50 ng of recombinant human CRP in a buffered protein base 
with preservatives 
Assay Diluent RD1F 6 mL of a buffered protein base with preservatives  
Calibrator Diluent RD1F 21 mL of a buffered protein base with preservatives 
Wash Buffer Concentrate 21 mL of a 25-fold concentrated solution of buffered 
surfactant with preservatives 
Color Reagent A 12 mL of stabilized hydrogen peroxide 
Color Reagent B 12 mL of stabilized chromogen 
Stop Solution 6 mL of 2 N sulfuric acid 
Human Serum Serum samples of participants 
Table 1. Reagents used during CRP ELISA. 
 
IL-6 Conjugate 21 mL of polyclonal antibody specific for human IL-6 
conjugated to horseradish peroxidase with preservatives 
IL-6 Standard 1.5 ng of recombinant human IL-6 in a buffered protein 
base with preservatives then lyophilized 
Assay Diluent RD1W 11 mL of a buffered protein base with preservatives  
Calibrator Diluent RD5T 21 mL of a buffered protein base with preservatives 
Calibrator Diluent RD6F 21 mL of animal serum with preservatives 
Wash Buffer Concentrate 21 mL of a 25-fold concentrated solution of buffered 
surfactant with preservatives 
Color Reagent A 12 mL of stabilized hydrogen peroxide 
Color Reagent B 12 mL of stabilized chromogen 
Stop Solution 6 mL of 2 N sulfuric acid 
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Human Serum Serum samples of participants 
Table 2. Reagents used during IL-6 Elisa 
3.5 Statistical Analysis 
The ELISA Data was analyzed using GraphPad Prism® software. Relationships between 
different factors (i.e. BMI, age, HAI concentration) were assed using the ANOVA test 
feature of the program. P-values <0.05 were deemed statistically significant.  
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CHAPTER 4: RESULTS 
4.1 Demographics of the Study Population 
The 17 participants were obese African-American females who were non-
diabetic, did not smoke, and had a BMI over 30. African-Americans were the focus of 
this study because they are an understudied population. Participants of this study were 
broken down into two different categories on three occasions based on their BMI, age, 
and response rates to HAI titers of the H3N2 Perth virus. Low obese BMI was defined as 
≤35 and high obese BMI as >35. Low age was defined as ≤50 and high age as >50. A low 
response to the H3N2 titer was defined as ≤240 and high response was defined as >240.  
Participant-ID Age BMI  Gender Race Diabetes Smoking 
03-602-02 59 30.4 Female aa no No 
03-971-02 42 35.0 Female aa no No 
03-681-02 46 38.8 Female aa no No 
03-738-02 42 52.4 Female aa no No 
03-783-02 26 36.6 Female aa no No 
03-817-02 64 31.8 Female aa no No 
03-934-02 53 33.8 Female aa no No 
03-633-02 54 38.6 Female aa no No 
03-815-02 57 30.3 Female aa no No 
03-978-02 54 34.1 Female aa no No 
03-939-02 77 31.5 Female aa no No 
03-948-02 23 54.7 Female aa no No 
03-733-02 48 38.5 Female aa no No 
03-714-02 51 41.1 Female aa no No 
03-804-02 63 36.1 Female aa no No 
03-552-02 37 61.4 Female aa no No 
03-671-02 20 36.5 Female aa no No 
Table 3. Demographics of the participants in this study. All the participants were 
African-American women with BMIs between 30.4 and 61.4 kg/m^2 . The average age 
of the participants was 48 and the average BMI was 38.9.  
 High Age 
Group  
Low Age 
Group 
Low BMI 
Group 
High BMI 
Group 
Low HAI 
Group 
High 
HAI 
Group 
Mean 59.1 35.5 32.4 43.5 85.7 624 
Table 4. Means of the selected groups and variables tested  
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4.2 Cytokine Levels in Serum (IL-6 and CRP) 
Participant-
ID Age BMI  
IL6 
Concentration 
(pg/mL) 
CRP 
Concentration 
(mg/L) 
HAI of 
Perth 
(H3N2) 
03-602-02 59 30.4 0.823 0.184 0 
03-971-02 42 35.0 0.727 0.819 0 
03-681-02 46 38.8 1.169 1.61 80 
03-738-02 42 52.4 20.629 1.599 80 
03-783-02 26 36.6 6.766 1.925 120 
03-817-02 64 31.8 1.892 1.243 160 
03-934-02 53 33.8 1.193 0.284 160 
03-633-02 54 38.6 1.241 0.651 320 
03-815-02 57 30.3 7.749 0.225 320 
03-978-02 54 34.1 1.954 0.894 320 
03-939-02 77 31.5 6.634 2.171 320 
03-948-02 23 54.7 7.05 2.094 320 
03-733-02 48 38.5 2.812 0.444 480 
03-714-02 51 41.1 4.798 1.976 640 
03-804-02 63 36.1 0.469 2.135 960 
03-552-02 37 61.4 5.731 2.221 1280 
03-671-02 20 36.5 2.857 1.533 1280 
Table 5. Average CRP and IL-6 levels in the serum of participants. All results were 
derived from the ELISA plate reader. 
Mean IL6 (pg/mL) CRP (mg/L) HAI for H3N2 
Low BMI 4.742714286 1.094857 85.714 
High BMI 4.1295 1.4344 624 
Table 6. Average IL6 and CRP values for the low and high BMI groups.  
 The data was taken from the plate reader and then analyzed using Prism’s 
ANOVA feature to find any correlations between serum levels of IL-6 and CRP and BMI 
value.  
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Graph 1. The IL-6 serum levels (in pg/mL) for the low obesity and high obesity groups 
were 2.996 ± 1.105, n=7 and 5.352 ± 1.855, n=10, respectively. There was no significant 
difference to conclude a link between BMI and IL-6 serum levels, as the p-value was 
equal to 0.1040.  
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Graph 2. The CRP serum levels (in mg/L) for the low obesity and high obesity groups 
were 0.8314 ± 0.2697, n=7 and 1.619 ± 0.1944, n=10, respectively. There was no 
significant difference to conclude a link between BMI and CRP serum levels., as the p-
value was 0.6598. 
 There seems to be a trend in this data towards higher levels of CRP in the high 
BMI group. Statistical significance is not reached though because of a limited number of 
subjects.  
 
 
Graph 3. The IL-6 serum levels (in pg/mL) for the low responding and high responding 
groups were 4.743 ± 2.767, n=7 and 4.130 ± 0.8215, n=10, respectively. There was a 
significant difference to conclude a link between response to HAI titers for H3N2 and IL-
6 serum levels, as the p-value was 0.0069.  
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Graph 4. The CRP serum levels (in mg/L) for the low responding and high responding 
groups were 1.095 ± 0.2579, n=7 and 1.434 ± 0.2525, n=10, respectively. There was no 
significant difference to conclude a link between response to HAI titers for H3N2 and 
CRP serum levels, as the p-value was 0.7245. 
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Graph 5. The IL-6 serum levels (in pg/mL) for the low and high age groups were 5.968 
± 2.264, n=8and 2.515 ± 0.8837, n=8, respectively. There was a significant difference to 
conclude a link between age and IL-6 serum levels, as the p-value was 0.0239. 
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Graph 6. The CRP serum levels (in mg/L) for the low and high age groups were 1.531 ± 
0.2174, n=8 and 0.9490 ± 0.2736, n=8, respectively. There was no significant difference 
to conclude a link between age and CRP serum levels., as the p-value was 0.5593.  
 There seems to be a trend in this data towards lower levels of CRP in the high age 
group. Statistical significance is not reached though because of a limited number of 
subjects. 
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CHAPTER 5: DISCUSSION 
5.1 Conclusions 
A subset of obese, non-diabetic, non-smoking African American women were 
investigated in this study to better understand factors that contribute to the variation in 
responses to the influenza vaccination. The original hypothesis stated that increased 
levels of IL-6 and CRP in subjects with a high BMI would be correlated with a lower 
response to vaccination. Obese individuals typically have higher levels of inflammation, 
and consequently, higher levels of IL-6 and CRP. Adipocytes serve as not only a means 
of storage for body energy but also as endocrine organs with metabolic roles that regulate 
the body’s physiology. Enlarged adipocytes in obese individuals promote inflammation 
through the recruitment of macrophages and the release of factors that also prompt 
insulin resistance.15 This study confirmed that obese individuals had higher 
concentrations of IL-6 and CRP compared to healthy weight individuals. It is important 
to note though that increasing obesity did not lead to an increase of in inflammatory 
markers within this study. This lack of significance may be attributed to the limited and 
non-diverse sample size, with respect to varying obesity. 
Overall, no significant link was found between increasing obesity and response to 
the influenza vaccine. Once an individual reaches obesity, or a BMI over 30, the levels of 
inflammation rates more or less taper off and become stagnant. Increases in obesity have 
not been shown to increase inflammation at the rate at which an individual approaching 
obesity would. Both IL-6 and CRP serum levels were deemed independent of body mass 
index. Both IL-6 and CRP serum levels were higher in these obese subjects than the 
normal levels for healthy weight people, which average below 1.0 mg/L.16 The low BMI 
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group had an average level of 1.09 mg/L and the high BMI group had an average level of 
1.43, further signifying that increased weight increases CRP levels. Increased body 
weight results in higher rates of inflammation so these results make sense. Normal IL-6 
levels are between 1-2 ug/mL.17 The lower BMI group had an average of 4.74 ug/mL of 
IL-6 in their serum while the high BMI group had an average of 4.12 ug/mL. These 
results are consistent with obese individuals having higher serum levels. The fact that the 
lower weight group had larger values than the higher way group may be a result of a 
rather limited sample size.  
The results from this experiment confirmed that there was statistically significant 
data to show a link between IL-6 serum levels and a response the HAI titer for the H3N2 
virus. The higher response group had lower IL-6 serum levels and the lower response 
group had high IL-6 serum levels. IL-6 is a cytokine that serves a variety of immune 
functions in response to acute illness or injury. As a pro-inflammatory cytokine, IL-6 is 
involved in activating inflammatory pathways. If IL-6 levels are low, then the body does 
not require any inflammation and is in a generally healthy state. Additionally, a 
significant difference was found to support a link between IL-6 serum levels and age. 
Younger subjects had higher IL-6 serum levels than older subjects.  
CRP is produced by the liver and rises when there is inflammation throughout the 
body. Its purpose is to activate the complement system, which helps antibodies clear 
pathogens from organisms, by attaching to dead cells after IL-6 is released. Surprisingly 
this particular study established links between age, HAI response, or BMI for CRP serum 
levels. These unforseen results may have been attributable to the small sample size.  
 
5.2 Limitations and Recommendation for Further Studies 
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This study had multiple limitations that may have skewed or produced inaccurate 
data. The CRP and IL-6 ELISA kits were both expired at the time of the experiment. This 
may have resulted in degraded standard and stopping solutions, and as a result produced 
inaccurate data outcomes for the subjects. Additionally the kits mays have lost a 
significant amount of sensitivity in the process. A degraded standard would have 
compared sample values to an incorrect value while a degraded stopping solution may 
have lost its effectiveness in stopping the reaction after the substrate was added because 
of a decreased concentration.  This ineffective stopping reagent would have resulted in 
overvalued concentrations of IL-6 and CRP in the samples. This limitation could be 
avoided in future experiments by procuring new ELISA kids ahead of time to ensure all 
products and solutions create accurate data. 
Another limitation of the experiment is that procedural mistakes may have 
occurred in the ELISA process. Four ELISA experiments were conducted concurrently, 
increasing the potential risk of error. Meticulous following of protocol is essential to 
ensuring accurate results. The subject samples were dispersed throughout the lab and had 
to be acquired in a timely manner before beginning the experiment. This resulted in the 
samples being thawed and refrozen on multiple occasions before being processed in the 
ELISA. The freezing and thawing process affects the levels of cytokines in the plasma. In 
future experiments, it is imperative that ELISA experiments are run immediately after the 
serum is collected.  
A major limitation in this experiment is that there was a small sample size of only 
17 subjects. There were only 17 obese African-American females available in the data set 
who did not have diabetes and who did not smoke. These subjects were chosen to limit 
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any differences in between subjects and get an accurate reading of just cytokine levels. 
Having a small data set reduced the statistical power of the study, making it difficult to 
account for the large variability in the results. Additionally, no lifestyle confounders or 
variables were considered. Subjects were not asked about their physical activity levels, 
eating habits, or about any other health conditions that could have affected cytokine 
levels. In future experiments, a larger sample size should be used and lifestyle factors 
should be considered. Furthermore, studying a non-obese group would be helpful as well 
to better understand the effects of BMI on cytokine levels.  
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